These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 15131529)
1. Clinical impact of stent construction and design in percutaneous coronary intervention. Lau KW; Mak KH; Hung JS; Sigwart U Am Heart J; 2004 May; 147(5):764-73. PubMed ID: 15131529 [TBL] [Abstract][Full Text] [Related]
3. A stent is not just a stent: Stent construction and design do matter in its clinical performance. Lau KW; Johan A; Sigwart U; Hung JS Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045 [TBL] [Abstract][Full Text] [Related]
4. Engineering aspects of stents design and their translation into clinical practice. Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159 [TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent. Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204 [TBL] [Abstract][Full Text] [Related]
6. Understanding the drug-eluting stent trials. Coolong A; Kuntz RE Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349 [TBL] [Abstract][Full Text] [Related]
7. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. Perin EC Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793 [TBL] [Abstract][Full Text] [Related]
8. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions. Ray GM; Nawarskas JJ; Frishman WH Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023 [TBL] [Abstract][Full Text] [Related]
9. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents. Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063 [TBL] [Abstract][Full Text] [Related]
11. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753 [TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090 [TBL] [Abstract][Full Text] [Related]
13. [Late stent thrombosis with drug eluting stents: disturbing signals on the radar]. Hansen PR Ugeskr Laeger; 2007 Apr; 169(17):1561-3. PubMed ID: 17484825 [TBL] [Abstract][Full Text] [Related]
14. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023 [TBL] [Abstract][Full Text] [Related]
15. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614 [TBL] [Abstract][Full Text] [Related]
16. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group. Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S; J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837 [TBL] [Abstract][Full Text] [Related]
17. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents. Wang TY; Hasselblad V; Peterson JL; Wijns W; Parhizgar A; Kereiakes DJ; Krucoff MW Am Heart J; 2007 May; 153(5):743-8. PubMed ID: 17452147 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related]
20. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world. Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]